GET DAILY SIGNALSImmunic, Inc. (IMUX): Can Shares Reach the $43 Analyst Target?
Key Takeaways
- The central stock price target of $43 is the arithmetic mean of the verified analyst price targets (rounded from $43.09), based on 13 targets tracked by S&P Global.
- The latest verified price near $7.51 implies roughly 470% upside to reach the target — a very large move.
- The analyst range is unusually wide, from $22 to $85, reflecting high uncertainty around a single binary clinical catalyst.
- Strongest supporting factors: a Phase 3 multiple sclerosis readout expected by the end of 2026 and a $200 million financing in early 2026 that eased the capital overhang.
- Biggest risks: a binary trial outcome, no approved products or recurring revenue, and the potential for further dilution.
- Explore Major News, Today's Price Move, the Forecast, and Earnings pages for deeper coverage of IMUX.
- Discover Trending AI Robots for additional signal-driven market tools.
Analyst Views and Price Targets
The $43 central target represents the average of verified analyst price targets rather than any single firm’s outlook. Recent attributed targets cover a broad spectrum: H.C. Wainwright at $22, Stifel Nicolaus at $25, B. Riley at $27, Roth MKM at $29, Wedbush at $45, and LifeSci Capital at $56, with the highest around $85. That $22-to-$85 spread is exceptionally wide for a small-cap biotech and shows analysts hold sharply different views on the value of IMUX’s pipeline. The overall rating stays strongly bullish, with most analysts at Buy or Strong Buy. Recent changes include Roth MKM lifting its target to $29 from $19 and B. Riley trimming its target to $27 from $40 while retaining a Buy rating, citing a “compelling entry point” ahead of the Phase 3 readout. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Valuation and Upside Potential
At a latest verified price near $7.51 and a market capitalization of roughly $102 million, IMUX would need an approximate 470% gain to reach the $43 target. Even the lowest analyst target of $22 still points to nearly 200% upside. The company reported no meaningful recurring revenue and a GAAP net loss of about $34.1 million in its most recent quarter, so any move toward the target rests almost entirely on clinical and regulatory developments rather than near-term fundamentals.
Factors That Could Drive the Stock Higher
A successful Phase 3 trial would validate the company’s oral approach in the competitive multiple sclerosis market and likely trigger upward revisions from analysts. The $200 million financing completed in early 2026 left total cash around $155 million, easing near-term capital concerns. Analysts also note a competitive landscape that has shifted in IMUX’s favor, and the Strong Buy consensus reflects broad confidence in the science even as targets remain measured relative to the potential upside from positive data.
Key Risks to Consider
The main risk remains clinical: a failed or mixed Phase 3 result would weaken the thesis and probably lead to lower targets. IMUX is still pre-revenue with no approved products, so its valuation depends on unproven assumptions about trial success, regulatory approval, and commercialization. The reverse stock split highlights prior price pressure, and companies at this stage often seek additional capital, which can dilute shareholders. The wide $22-to-$85 analyst range further illustrates material disagreement even among bullish voices.
Technical Picture and Levels to Watch
On a split-adjusted basis, IMUX has traded in a 52-week range of roughly $5.06 to $17.43. The $5 area serves as key support, while the prior high near $17.43 stands as the most relevant resistance the stock would need to clear before any sustained move toward higher targets. Round-number levels such as $10 and $15 may act as psychological hurdles, and the long-term structure remains that of a pre-commercial biotech driven more by catalysts than conventional technical patterns.
Key Dates and Catalysts to Monitor
Analyst price targets generally reflect a 12-month horizon. The most important near-term items include the Phase 3 multiple sclerosis readout expected by the end of 2026, the next earnings report and cash-burn commentary, any new analyst revisions, and updates on regulatory strategy or partnerships. Because the stock is catalyst-driven, the timing and content of clinical news matter more than quarterly results in the short term.
Final Assessment
The $43 target is the arithmetic mean of 13 verified analyst price targets ranging from about $22 to $85. Reaching it would require a gain of roughly 470% from the latest price near $7.51 — an exceptionally large move that hinges almost entirely on the Phase 3 multiple sclerosis trial expected by the end of 2026. Positive data and subsequent analyst revisions offer the clearest support, while a failed or inconclusive trial, continued cash burn, and dilution remain the principal obstacles. The unusually wide target range underscores genuine disagreement among analysts, and investors should monitor the clinical readout and any resulting target changes rather than treating the average as a guaranteed outcome.
Using Tickeron’s AI Daily Buy/Sell Signals
In my research process I frequently review Tickeron’s AI Daily Buy/Sell Signals to monitor trend shifts in volatile names like IMUX. The tool applies artificial intelligence across thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and market conditions. For a catalyst-driven stock, these signals help highlight momentum changes ahead of key clinical events without replacing full fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMUX's RSI Indicator ascends from oversold territory
The RSI Indicator for IMUX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 28 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on IMUX as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 215 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
IMUX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 53 cases where IMUX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for IMUX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMUX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.785) is normal, around the industry mean (3.104). P/E Ratio (-2.068) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IMUX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
Industry Biotechnology
Advertisement